EVLO — Evelo Biosciences Share Price
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.01m
- $16.69m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Evelo Biosciences, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing a class of oral medicines that act on immune cells in the small intestine with systemic effects. Its small intestinal axis (SINTAX) is the network of connections that links the small intestine and the rest of the body. Immune cells and other cells in the small intestine act as sentinels and are constantly sensing the contents of the gut. Depending on what is sensed, these cells relay messages from the gut to the rest of the body that modulate systemic immunity. Its orally delivered product candidates are pharmaceutical compositions of specific single strains of commensal microbes or the extracellular vesicles (EVs) they shed.
Directors
- David Epstein CHM (59)
- Balkrishan Gill PRE (56)
- Luca Scavo CFO (54)
- Mark Bodmer CSO (64)
- Daniel Char GCN (60)
- Duncan McHale OTH (54)
- Jonathan Zung OTH (56)
- Iain Mcinnes DRC
- Juan Andres IND (56)
- Lord Ara Darzi IND (60)
- John Hohneker IND
- Julie Mchugh IND (56)
- Theodose Melas-Kyriazi IND (61)
- David Perry IND (53)
- Nancy Simonian IND (60)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- May 6th, 2014
- Public Since
- May 9th, 2018
- No. of Shareholders
- 26
- No. of Employees
- 66
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 18,930,960
- Address
- 124 WASHINGTON STREET, SUITE 101, FOXBORO, 02035
- Web
- https://evelobio.com/
- Phone
- +1 6175770300
- Auditors
- Ernst & Young LLP
Upcoming Events for EVLO
Q2 2024 Evelo Biosciences Inc Earnings Release
Q3 2024 Evelo Biosciences Inc Earnings Release
Similar to EVLO
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
What is the Evelo Biosciences share price?
As of Today at 20:32 UTC, shares in Evelo Biosciences are trading at $0.00. This share price information is delayed by 15 minutes.
How has the Evelo Biosciences share price performed this year?
Shares in Evelo Biosciences last closed at $0.00 and the price had moved by -99.39% over the past 365 days. In terms of relative price strength the Evelo Biosciences share price has underperformed the S&P500 Index by -99.44% over the past year.
What are the analyst and broker recommendations for Evelo Biosciences?
The overall consensus recommendation for Evelo Biosciences is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Evelo Biosciences dividend yield?
Evelo Biosciences does not currently pay a dividend.
Does Evelo Biosciences pay a dividend?
Evelo Biosciences does not currently pay a dividend.
When does Evelo Biosciences next pay dividends?
Evelo Biosciences does not currently pay a dividend.
How do I buy Evelo Biosciences shares?
To buy shares in Evelo Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Evelo Biosciences?
As of the previous close price of $0.00, shares in Evelo Biosciences had a market capitalisation of $0.01m.
Where are Evelo Biosciences shares listed?
Here are the trading details for Evelo Biosciences:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: EVLO
What kind of share is Evelo Biosciences?
Based on an overall assessment of its quality, value and momentum Evelo Biosciences is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Evelo Biosciences share price forecast for 2025?
The analyst consensus target price for shares in Evelo Biosciences is $10.00. That is 3333233.33% above the last closing price of $0.00.
Analysts covering Evelo Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$6.70 for the next financial year.
Find out moreWhat is the trend in the Evelo Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Evelo Biosciences. Over the past six months, its share price has outperformed the S&P500 Index by +0.27%.
As of the last closing price of $0.00, shares in Evelo Biosciences were trading -98.92% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Evelo Biosciences PE Ratio?
The Evelo Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Evelo Biosciences?
Evelo Biosciences' management team is headed by:
- David Epstein - CHM
- Balkrishan Gill - PRE
- Luca Scavo - CFO
- Mark Bodmer - CSO
- Daniel Char - GCN
- Duncan McHale - OTH
- Jonathan Zung - OTH
- Iain Mcinnes - DRC
- Juan Andres - IND
- Lord Ara Darzi - IND
- John Hohneker - IND
- Julie Mchugh - IND
- Theodose Melas-Kyriazi - IND
- David Perry - IND
- Nancy Simonian - IND